anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systems and methods are provided for providing decision making support in healthcare. A user is able to provide healthcare data, including qualifier, indications, body part modifiers, body parts, modality modifiers, modalities, procedures and protocols. A graphical user interface (GUI) is provided to allow procedure rules to be created by selecting components of the healthcare data. The procedure rules identify and recommend appropriate procedures based on user input. The GUI also allows for global rules, body part rules, modality rules and modality modifier rules to be created; these rules are contra-indicators to procedures. Upon establishing the rules, a physician can enter data about a patient into the system, and the system will use the rules to return one or more appropriate procedures.
BACKGROUND: For Clostridioides difficile infections (CDIs) in Germany no longitudinal multi-centre studies with standardized protocols for diagnosing CDI are available. Recent evaluations of general surveillance databases in Germany indicate a downward trend in CDI rates. We aimed to describe the actual burden and trends of CDI in German university hospitals from 2016 to 2020.
METHODS: Our study was a prospective multi-centre study covering six German university hospitals. We report the data in total, stratified by year, by medical specialty as well as by CDI severity. Multi-variable regression analyses were performed to assess risk factors for severe CDI.
RESULTS: We registered 3780 CDI cases among 1,436,352 patients. The median length of stay (LOS) of CDI cases was 20 days (interquartile range 11-37) compared with a general LOS of 4.2 days. In-hospital all-cause mortality in CDI patients was 11.7% (N = 444/3780), while mortality attributed to CDI was 0.4% (N = 16/3761). CDI recurrence rate was comparatively low at 7.2%. The incidence density of severe healthcare-associated healthcare onset (HAHO)-CDI showed a significant decrease from 2.25/10,000 patient days (pd) in 2016 to 1.49/10,000 pd in 2020 (trend calculation P=0.032).
CONCLUSIONS: Compared with a European point-prevalence study in 2013/2014, where overall CDI incidence density was 11.2 cases/10,000 pd in Germany (EUCLID), we see in our study halved overall CDI rates of 5.6 cases/10,000 pd in 2020. Our study shows current data on the distribution of CDI cases in German university hospitals and thus provides international comparative data on the key indicators of CDI.
<P>PROBLEM TO BE SOLVED: To clarify a vegetable component effective for neutralizing antigenicity of a virus and provide the vegetable component having immunoglobulin-like activity.  <P>SOLUTION: A vegetable eaten by human as a food is defatted with ethanol and extracted with a weakly alkaline water. The extracted liquid is treated with a centrifugal concentration filter to extract a component having a molecular weight of 150,000-180,000. The skin of the vegetable eaten by human is potato skin, rice bran, adzuki bean skin or squeezed cake of Panax ginseng. Viral infection through mucosa can be prevented by including the component in candy, chewing gum, troche, etc.  <P>COPYRIGHT: (C)2011,JPO&INPIT
A monitoring system includes a selection module configured to receive operational requirements, a database of conditions, a condition module, and at least one validation system. The condition module is responsive to the selection module and in communication with the database of conditions. The condition module is configured to select conditions from the database based on the received operational requirements. The at least one validation system receives the selected conditions from the condition module and determines a validation. 12100 14105 Selection Condition Conditions module module Condition 103 Validation 106b 1/0 ~system 16 interface 106 Lock module Fig. 1
Diffuse axonal injury (DAI) is a critical pathological facet of traumatic brain injury (TBI). Oxidative stress plays a significant role in the progress of DAI. Annexin A1 (AnxA1) has been demonstrated to benefit from recovery of neurofunctional outcomes after TBI. However, whether AnxA1 exhibits neuronal protective function by modulating oxidative stress in DAI remains unknown. Expression of AnxA1 was evaluated via real-time PCR and western blotting in rat brainstem after DAI. The neurological effect of AnxA1 following DAI through quantification of modified neurologic severity score (mNSS) was compared between wild-type and AnxA1-knockout rats. Brain edema and neuronal apoptosis, as well as expression of oxidative factors and inflammatory cytokines, were analyzed between wild-type and AnxA1 deficiency rats after DAI. Furthermore, mNSS, oxidative and inflammatory cytokines were assayed after timely administration of recombinant AnxA1 for DAI rats. In the brainstem of DAI, the expression of AnxA1 remarkably increased. Ablation of AnxA1 increased the mNSS score and brain water content of rats after DAI. Neuron apoptosis in the brainstem after DAI was exaggerated by AnxA1 deficiency. In addition, AnxA1 deficiency significantly upregulated the level of oxidative and inflammatory factors in the brainstem of DAI rats. Moreover, mNSS decreased by AnxA1 treatment in rats following DAI. Expression of oxidative and inflammatory molecules in rat brainstem subjected to DAI inhibited by AnxA1 administration. AnxA1 exhibited neuronal protective function in the progression of DAI mainly dependent on suppressing oxidative stress and inflammation.
BACKGROUND: The role of BMAL1 in various diseases remains unclear, particularly its impact on sepsis-induced acute kidney injury (AKI). This study aims to investigate the role of BMAL1 in sepsis-induced AKI and its potential effects on cell ferroptosis. Initially, we assessed BMAL1 expression levels in mice treated with sepsis-induced AKI (via LPS injection) and in LPS-stimulated renal tubular epithelial cells. Subsequently, we explored the correlation between BMAL1 and ferroptosis using sequencing technology, validating our findings throughout experimental approaches. To further elucidate BMAL1's specific effects on AKI-related ferroptosis, we constructed BMAL1 overexpression models in mice and cells, analysing its impact on AKI and ferroptosis both in vivo and in vitro. Furthermore, using transcriptome sequencing technology, we identified key BMAL1-regulated genes and their associated biological pathways, validating these findings through in vivo and in vitro experiments.
RESULTS: Our findings indicate decreased BMAL1 expression in sepsis-induced AKI. BMAL1 overexpression effectively mitigated renal tubular injury by reducing ferroptosis levels in renal tubular epithelial cells. Using transcriptome sequencing and ChIP-qPCR technology, we identified YAP as a target of BMAL1. The overexpression of BMAL1 significantly reduced the transcriptional activity of YAP and inhibited the Hippo signalling pathway. Treatment with the Hippo inhibitor Verteporfin (VP) reversed the BMAL1-downregulation-induced damage. Additionally, our study revealed that YAP positively regulates ACSL4 gene expression and its downstream signalling pathways.
CONCLUSION: This study demonstrates that BMAL1 overexpression alleviates renal tubular epithelial cell injury and ferroptosis by inhibiting YAP expression and the Hippo pathway, thereby exerting protective effects in sepsis-induced AKI. These findings underscore the therapeutic potential of targeting BMAL1 in managing sepsis-induced AKI.
Placebo is administered every 2 weeks for the first 16 weeks. GR1802 is given every 2 weeks from week 24 to W50.
FIELD: pharmacology, veterinary science. SUBSTANCE: preparation has biologically active plant and propolis substances in complex with dimexide, synthetic high- and low-molecular polyethylene oxides at the following ratio of components, wt.-%: extract of plant raw in dimexide 5-15; propolis 5-15; high-molecular polyethylene oxides 10-30; low-molecular polyethylene oxides up to 100. Polyethylene oxide of molecular mass 1000-7000 Da and polyethylene oxide of molecular mass 200-400 Da were used as high- and low-molecular polyethylene oxides, respectively. Medicinal preparation is prepared by extraction of plant raw with absolute dimexide by two stages at 90-100 C and total time 2-4 h. Then propolis is extracted in dimexide extract of plant raw at 60-70 C for 2 h. In settled extract polyethylene oxides were dissolved. Preparation can be prepared as liniment, ointment, suppository that depends on polyethylene oxide molecular mass and their quantitative ratio. EFFECT: improved method of preparing, enhanced effectiveness. 3 cl, 6 tbl
INTRODUCTION: The femoral head contralateral to the collapsed femoral head requiring total hip arthroplasty (THA) often manifests in the precollapse stage of osteonecrosis of the femoral head (ONFH). It is not yet demonstrated how autologous concentrated bone marrow injection may prevent collapse of the femoral head concurrent with contralateral THA. The primary objective is to evaluate the efficacy of autologous concentrated bone marrow injection for the contralateral, non-collapsed, femoral head in patients with bilateral ONFH, with the ipsilateral collapsed femoral head undergoing THA.
METHODS AND ANALYSIS: This is a multicentre, prospective, non-randomised, historical-data controlled study. We will recruit patients with ONFH who are scheduled for THA and possess a non-collapsed contralateral femoral head. Autologous bone marrow will be collected using a point-of-care device. After concentration, the bone marrow will be injected into the non-collapsed femoral head following the completion of THA in the contralateral hip. The primary outcome is the percentage of femoral head collapse evaluated by an independent data monitoring committee using plain X-rays in two directions 2 years after autologous concentrated bone marrow injection. Postinjection safety, adverse events, pain and hip function will also be assessed. The patients will be evaluated preoperatively, and at 6 months, 1 year and 2 years postoperatively.
ETHICS AND DISSEMINATION: This protocol has been approved by the Certified Committee for Regenerative Medicine of Tokyo Medical and Dental University and Japan's Ministry of Healthy, Labour and Welfare and will be performed as a class III regenerative medicine protocol, in accordance with Japan's Act on the Safety of Regenerative Medicine. The results of this study will be submitted to a peer-review journal for publication. The results of this study are expected to provide evidence to support the inclusion of autologous concentrated bone marrow injections in the non-collapsed femoral head in Japan's national insurance coverage.
TRIAL REGISTRATION NUMBER: jRCTc032200229.
"TEETH" is a double-blinded, randomized clinical trial, supervised by a Data \& Safety Monitoring Board, designed to provide unequivocal evidence regarding the impact of regular rinsing 0.12% chlorhexidine solution on tooth loss in low income, community-dwelling older adults who are irregular users of dental services. Of the 1101 subjects enrolled in the study in Seattle, WA and Vancouver, B.C., one/half have been assigned to the active rinse condition; the other half to the placebo rinse which looks and tastes like the chlorhexidine rinse but does not have the active ingredient. Subjects receive two bottles of rinse every six months; the first to be used daily for one month, the second weekly for five months. Reminder calls are designed to help subjects maintain this rinse regimen. Subjects return yearly to research clinics at each participating university, where they are examined by a dentist who is trained in clinical research methodology and calibrated annually. The purpose of these visits is to examine subjects for tooth loss (followed by contacts with extracting dentists to determine the dentist's reasons for extracting the tooth), pocket depth, recession, caries and restorations on root and coronal surfaces. Interviews are also conducted annually with participants to assess health status, health behaviors, and oral health quality of life. A panoramic radiograph was taken at baseline of each subject and is to be done again at the five-year (final) yearly exam. These radiographs are used to confirm tooth loss and possible reasons for extractions
PURPOSE:Antibiotic SS21020E having improved inhibitory action on tumor cell multiplication, collected from a culture mixture of Streptomyces sp. strain S21020. CONSTITUTION:A bacterium capable of producing the antibiotic SS21020E is Streptomyces sp. strain S21020(FERM P-7997). The antibiotic SS21020E is obtained by inoculating the strain into a nutritive source-containing medium, and cultivating it aerobically. In the culture, a common culture method of actinomycetes can be used, and especially submerged spinner culture method is most suitable. Isolation of SS21020E from the culture solution is carried out by separating a mold from the culture mixture by centrifugal separation, filtration, etc., and performing an ordinary separating means from the mold or a culture filtrate.
Hypoxic-ischemic encephalopathy (HIE) poses a significant challenge in neonatal medicine, often resulting in profound and lasting neurological deficits. Current therapeutic strategies for hypoxia-ischemia brain damage (HIBD) remain limited. Ferroptosis has been reported to play a crucial role in HIE and serves as a potential therapeutic target. However, the mechanisms underlying ferroptosis in HIBD remain largely unclear. In this study, we found that elevated lysyl oxidase (LOX) expression correlates closely with the severity of HIE, suggesting LOX as a potential biomarker for HIE. LOX expression levels and enzymatic activity were significantly increased in HI-induced neuronal models both in vitro and in vivo. Notably, we discovered that HI-induced brain tissue injury results in increased stiffness and observed a selective upregulation of the mechanosensitive ion channel Piezo1 in both brain tissue of HIBD and primary cortex neurons. Mechanistically, LOX increases its catalytic substrates, the Collagen I/III components, promoting extracellular matrix (ECM) remodeling and possibly mediating ECM cross-linking, which leads to increased stiffness at the site of injury and subsequent activation of the Piezo1 channel. Piezo1 senses these stiffness stimuli and then induces neuronal ferroptosis in a GPX4-dependent manner. Pharmacological inhibition of LOX or Piezo1 ameliorated brain neuronal ferroptosis and improved learning and memory impairments. Furthermore, we identified traumatic acid (TA) as a novel LOX inhibitor that effectively suppresses LOX enzymatic activity, mitigating neuronal ferroptosis and promoting synaptic plasticity. In conclusion, our findings elucidate a critical role for LOX-mediated ECM mechanical stress-induced Piezo1 activation in regulating ferroptotic cell death in HIBD. This mechanistic insight provides a basis for developing targeted therapies aimed at ameliorating neurological outcomes in neonates affected by HIBD.
Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
State-of-the-art response assessment of central nervous system lymphoma (CNSL) by magnetic resonance imaging is challenging and an insufficient predictor of treatment outcomes. Accordingly, the development of novel risk stratification strategies in CNSL is a high unmet medical need. We applied ultrasensitive circulating tumor DNA (ctDNA) sequencing to 146 plasma and cerebrospinal fluid (CSF) samples from 67 patients, aiming to develop an entirely noninvasive dynamic risk model considering clinical and molecular features of CNSL. Our ultrasensitive method allowed for the detection of CNSL-derived mutations in plasma ctDNA with high concordance to CSF and tumor tissue. Undetectable plasma ctDNA at baseline was associated with favorable outcomes. We tracked tumor-specific mutations in plasma-derived ctDNA over time and developed a novel CNSL biomarker based on this information: peripheral residual disease (PRD). Persistence of PRD after treatment was highly predictive of relapse. Integrating established baseline clinical risk factors with assessment of radiographic response and PRD during treatment resulted in the development and independent validation of a novel tool for risk stratification: molecular prognostic index for CNSL (MOP-C). MOP-C proved to be highly predictive of outcomes in patients with CNSL (failure-free survival hazard ratio per risk group of 6.60; 95% confidence interval, 3.12-13.97; P < .0001) and is publicly available at www.mop-c.com. Our results highlight the role of ctDNA sequencing in CNSL. MOP-C has the potential to improve the current standard of clinical risk stratification and radiographic response assessment in patients with CNSL, ultimately paving the way toward individualized treatment.
The invention discloses an externally applied ointment for treating children eczema, which is composed of the following raw medicines: 20-30g of Atractylis ovata, 20-30g of angelica, 20-30g of white peony root, 10-20g of figwort root, 10-20g of plantain, 10-20g of fungus umbellatus, 5-15g of radix scutellariae, 5-15g of coptis and 5-15g of borneol. The externally applied ointment is prepared by the following steps of: pulverizing the raw medicines, screening with a 20-mesh sieve, uniformly mixing, adding medical vaseline or glycerine and processing into the ointment. The ointment is used by applying on an affected part two or three times a day and then gently massaging for a while. The externally applied ointment provided by the invention has the functions of clearing away heat, detoxifying, eliminating rash, relieving itching, expelling wind and removing dampness, and can be used for treating children eczema. In 53 cases of patients treated with the externally applied ointment, 48 cases are cured, and the effective rate reaches 90.6%. The externally applied ointment provided by the invention has the advantages good efficacy, rapid acting, low recurrence rate after curing, low cost, etc.
Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further, the methods of making such compositions are also provided. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter and optionally a membrane transduction domain of a viral protein. Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. Methods for treating disc disease associated with trauma or disc degeneration are also described.
PURPOSE: A composition containing red garlic extract is provided to suppress reduction of respiratory intracellular glutathione concentrations and to treat and prevent diseases caused by respiratory cell apoptosis. CONSTITUTION: A composition for preventing or treating diseases caused by respiratory cell apoptosis contains red garlic extract as an active ingredient. The apoptosis of respiratory cells is induced by cigarette smoke inhalation. The red garlic extract is isolated by hot water. A pharmaceutical composition for preventing or treating diseases caused by respiratory cell apoptosis contains the red garlic extract as an active ingredient. A composition for suppressing reduction of intracellular glutathione concentration in respiratory contains the red garlic extract as an active ingredient.
The invention discloses an actinobacillus pleuropneumoniae immunoprotective antigen protein APJL _0922 and application thereof. The amino acid sequence of the actinobacillus pleuropneumoniae immunoprotection antigen protein is shown as SEQ ID NO.1, the immunoprotection antigen protein consists of 273 amino acids, and the mature polypeptide part of the immunoprotection antigen protein is 20-273 amino acids. The nucleotide sequence for coding the immunoprotective antigen protein is preferably shown as SEQ ID NO. 2. The immunoprotective antigenic protein disclosed by the invention has good immunogenicity and strong immunoprotection effect, and has the application of preparing a kit for detecting actinobacillus pleuropneumoniae antibodies, preparing a porcine pleuropneumonia subunit vaccine and preparing a medicament for preventing diseases caused by actinobacillus pleuropneumoniae. The invention provides a new material for preparing the porcine pleuropneumonia subunit vaccine and has important significance for preventing and controlling the porcine pleuropneumonia.
Random-order cross-over participants managed by ENDOCRINOLOGY with TELEHEALTH visits, assigned by randomization to undergo 14 days of Usual Care, followed by 14 days of Bionic Pancreas. There was no washout period between arms.
INTRODUCTION: Antimuscarinics are often the first-choice medications used to treat overactive bladder (OAB), a condition that increasingly affects the aging population. However, concerns regarding their potential impact on cognitive function have persisted for more than a decade.
AREAS COVERED: This review was conducted to update the literature on the cognitive safety profiles of various antimuscarinics, integrating findings from both recent and earlier studies to present an updated and comprehensive analysis. A search of English-language publications, including electronic databases and gray literature, focused on the cognitive impacts of antimuscarinics, resulting in a review and assessment of diverse studies and their associated outcomes.
EXPERT OPINION: Oxybutynin requires caution due to potential adverse effects, suggesting a need to consider alternative therapies. Darifenacin, while promising in preserving cognitive function, warrants further investigation for use in dementia patients. Fesoterodine has shown tolerance without cognitive decline in controlled trials. However, Tolterodine and Solifenacin present conflicting evidence regarding cognitive impairment and dementia risk, respectively, necessitating additional research to ascertain their safety profiles. Careful monitoring and treatment of patients taking these medications for cognitive impairment are essential. Further research, particularly in vulnerable populations, is crucial to establish cognitive safety profiles of various antimuscarinics and inform optimal OAB treatment strategies.
Octreotide acetate injection alters the balance between the counter-regulatory hormones, insulin, glucagon and GH, which may result in hypoglycemia or hyperglycemia. The hypoglycemia or hyperglycemia which occurs during octreotide acetate injection therapy is usually mild but may result in overt diabetes mellitus or necessitate dose changes in insulin or other anti-diabetic agents. Hypoglycemia and hyperglycemia occurred on octreotide acetate injection in 3% and 16% of acromegalic patients, respectively [see Adverse Reactions (6)]. Severe hyperglycemia, subsequent pneumonia, and death following initiation of octreotide acetate injection therapy was reported in one patient with no history of hyperglycemia.  
  
Monitor glucose levels during octreotide acetate injection therapy. Adjust dosing of insulin or other anti-diabetic therapy accordingly.
NEW MATERIAL:A compound shown by formula I (R is methyl, tert-butyl, methoxy or OH). EXAMPLE:4-Dimetnylamino-4'-methylbenzophenone. USE:Useful as a compound to be added to coating compounds, plastics, synthetic fibers, etc., and to provide them with ultraviolet light absorbing ability. Also useful as anti-suntan agent for cosmetics such as lotion, cream, hair dressing agent, etc. Effectively absorbing ultraviolet rays of long wavelength, having wide absorption range and excellent stability free from skin irritation. PREPARATION:A benzanilide derivative shown by the formula II is reacted with dimethylaniline in the presence of a catalyst such as phosphorus oxychloride, etc., in a solventless state at 120-150 deg.C. Then the reaction product is hydrolyzed with dilute hydrochloric acid, etc., to give a compound shown by formula I.